Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Drug Profile

Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Alternative Names: ASP 7373; Avian influenza (bird flu) vaccine - Protein Sciences Corporation/UMN Pharma; H7-rHA; HA vaccine for H5N1 (UMN 0501) - Protein Sciences Corporation; HA vaccine for H9N2 (UMN 0901) - Protein Sciences Corporation; Influenza A (H1N1) vaccine - Protein Sciences Corporation/Vaxine; Influenza A virus H5N1 vaccine - UMN Pharma; Influenza A virus H7N9 vaccine - Protein Sciences Corporation; Panblok; PanBlok; Panblok H1/2009; Panblok-H7; Pandemic H5N1 influenza vaccine - Protein Sciences Corporation/UMN Pharma; Pandemic influenza virus (swine flu) vaccine - Vaxine; Recombinant H5 (rH5) pandemic influenza vaccine (Panblok) - Protein Sciences Corporation; Recombinant haemagglutinin (rHA) influenza vaccine; Recombinant influenza H5N1 vaccine (UMN-0501) - UMN Pharma; UMN 0901; UMN-0501

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Ildong Pharmaceutical; Protein Sciences Corporation; UMN Pharma; Vaxine
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza A virus H9N2 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
  • Preclinical Influenza A virus H9N2 subtype
  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Nov 2017 UMN 0901 is still in preclinical trials for Influenza-A virus H9N2 subtype (prevention) in China, Hong Kong, Japan, Singapore, South Korea and Taiwan
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in Australia (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A virus H9N2 subtype(Prevention) in China (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top